Potential human immunotherapeutics for plague

Two monoclonal antibodies directed to the V antigen of have been tested for protective efficacy in a murine model of bubonic plague. Mice were infected with a current clinical isolate from Madagascar, designated 10-21/S. Mab7.3, delivered to mice intra-periteoneally at either 24 h prior to, or 24 h...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy advances Vol. 1; no. 1; p. ltab020
Main Authors Andrianaivoarimanana, Voahangy, Randriantseheno, Lovasoa Nomena, Moore, Kristoffer M, Walker, Nicola J, Lonsdale, Steven G, Kempster, Sarah, Almond, Neil A, Rajerison, Minoarisoa, Williamson, E Diane
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.01.2021
Subjects
Reviews
clinical isolate
Plague
protection
immunotherapeutic
passive therapy
Online AccessGet full text

Cover

More Information
Summary:Two monoclonal antibodies directed to the V antigen of have been tested for protective efficacy in a murine model of bubonic plague. Mice were infected with a current clinical isolate from Madagascar, designated 10-21/S. Mab7.3, delivered to mice intra-periteoneally at either 24 h prior to, or 24 h post-infection, was fully protective, building on many studies which have demonstrated the protective efficacy of this Mab against a number of different clinical isolates of . Mab 29.3, delivered intra-peritoneally at either -24 h or +24 h, protected 4/5 mice in either condition; this has demonstrated the protective efficacy of this Mab for the first time. These results add to the cumulative data about Mab7.3, which is currently being humanized and highlight its potential as a human immunotherapeutic for plague, which is an enduring endemic disease in Madagascar and other regions of Africa, Asia, and South America.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2732-4303
2732-4303
DOI:10.1093/immadv/ltab020